CHICAGO / May 02, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC), is announcing that its Vice President and Chief Financial Officer, Jay Saccaro will be presenting at the following upcoming investor conferences.
These events can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
| Last Trade: | US$78.00 |
| Daily Change: | -0.57 -0.73 |
| Daily Volume: | 5,530,118 |
| Market Cap: | US$35.600B |
May 01, 2024 April 30, 2024 April 29, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
